Imvaggis

Estriol, the active ingredient in Imvaggis, is an estrogen presented as a vaginal formulation for vaginal use. It is employed to alleviate estrogen‑deficiency related conditions in postmenopausal women, such as vaginal atrophy and urogenital discomfort.

GNH USA supplies Imvaggis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to EU GMP standards and provides batch‑tested, temperature‑controlled shipments to meet the needs of diverse healthcare providers.

Estriol is used in hormone replacement therapy to address estrogen‑deficiency conditions affecting the urogenital tract, particularly in postmenopausal women. - Vaginal atrophy: Improves thinning of the vaginal epithelium and reduces dryness. - Menopausal symptoms related to estrogen deficiency: Alleviates burning, itching and discomfort during menopause. - Urogenital symptoms in postmenopausal women: Restores lubrication and reduces urinary irritation. - Genitourinary syndrome of menopause (GSM): Improves overall genital health and comfort.

Estriol administered vaginally may be associated with a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Vaginal irritation or burning: mild discomfort at the application site. - Discharge or spotting: transient vaginal bleeding or increased secretions. - Headache: mild to moderate headache episodes. - Nausea: occasional feeling of nausea.

Serious or Rare Side Effects: - Endometrial hyperplasia: abnormal thickening of the uterine lining. - Breast tenderness or enlargement: persistent swelling or pain. - Thromboembolic events: rare clot formation in veins or arteries. - Allergic reaction: rash, itching, swelling, or anaphylaxis.

When prescribing vaginal estriol, clinicians should consider several precautionary measures to ensure safe use. - Indication verification: Confirm estrogen‑deficiency symptoms before initiating therapy. - Duration of use: Limit continuous treatment to the shortest effective period, typically up to 12 weeks, unless reassessed. - Concomitant estrogen therapy: Avoid using with other systemic estrogen products to prevent excess exposure. - History of hormone‑sensitive cancers: Use with caution or avoid in patients with breast or endometrial cancer. - Monitoring: Assess vaginal health and symptom relief regularly; discontinue if adverse effects arise. - Store at ambient temperature: Keep the product below 25 °C in the original packaging, protected from moisture and direct sunlight.

Estriol may interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Anticoagulants (e.g., warfarin): Increased risk of bleeding. - Hormonal contraceptives: Potential additive estrogen effects. - Tamoxifen or aromatase inhibitors: May reduce therapeutic benefit.

Moderate Interactions (Monitor Closely): - Antihypertensives: Estriol can affect blood pressure control. - Thyroid hormone replacement: May require dose adjustment. - Certain antifungal agents (e.g., ketoconazole): May influence estriol metabolism.